Reported 23 days ago
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage biotech firm focused on endocrine treatments, has recently seen its shares drop significantly, losing 39.75% over the last year. The company has promising products in development, including Paltusotine for acromegaly and Atumelnant for congenital adrenal hyperplasia, but faces challenges with clinical data that could hinder stock performance. While some analysts see potential in CRNX over time, they suggest exploring AI stocks which offer higher returns and lower risks in the short term.
Source: YAHOO